IDT. In August 2010, we entered into a license agreement with Integrated DNA Technologies, or IDT, related to the use of blocked primers in combination with HDA. The term of this license agreement extends until the expiration of all the patents associated with the licensed patent rights, or until such time as we elect to terminate with 90 days’ notice. The license is exclusive to the fields of amplification utilizing HDA and detection of diagnostic targets in human in-vitro diagnostic testing, but is non-exclusive to all oncology and human papilloma virus targets or markers. These technologies have resulted in four pending U.S. patent applications and one issued European patent. We pay a royalty fee for the license of this technology based on a percentage of our “Net Sales” of products using these technologies (as defined in the license agreement). See Schedule 3(v)(i). Wrongful termination complaint filed in the United States District Court in and for the District of Utah, Central Division by a former employee, ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, against Great Basin Scientific, Inc. on June 15, 2016. Patent Title US 14/108,630 Systems and methods for point of care amplification and detection of nucleic acids (continuation, HDA, kit claims) CA2715890 Systems and methods for point of care amplification and detection of nucleic acids (general method) EP15182599.9 (divisional from ‘84) Systems and methods for point of care amplification and detection of nucleic acids (general method) EP08853920.0 Methods and compositions for amplifying a detectable signal US 14/949,240 Methods and compositions for amplifying a detectable signal (continuation, generalize target, methods of use/prep) CA2705984 Methods and compositions for amplifying a detectable signal US 13/911,878 Analyzer and Disposable Cartridge for Molecular In Vitro Diagnostics CA2881200 Characterization of a blocked-primer mediated isothermal amplification system JP2014-557780 Characterization of a blocked-primer mediated isothermal amplification system EP13748794.8 Methods of Isothermal Amplification Using Blocked Primers (system/kit claims) HK 15105687.0 Methods of Isothermal Amplification Using Blocked Primers (system/kit claims) US 14/565,696 Methods of Isothermal Amplification Using Blocked Primers (methods claims) US 14/883,018 SPECIFIC DETECTION OF ORGANISMS DERIVED FROM A SAMPLE (methods claims) US 14/7452,345 SPECIFIC DETECTION OF ORGANISMS DERIVED FROM A SAMPLE (kit claims) Patent Title Holder PCT/US2006/000406 Identification of RNA targets using helicase BioHelix 12/507,142 Rnase-H-based assays utilizing modified RNA monomers (bp method) IDT 13/839,334 Rnase-H-based assays utilizing modified RNA monomers (RNA targets) IDT 13/429,077 Rnase-H-based assays utilizing modified RNA monomers (Hot start language) IDT BioHelix. We hold non-exclusive licenses to key technologies from BioHelix related to isothermal amplification of nucleic acid targets, utilizing helicase-dependent amplification, or HDA. The term of this license agreement extends until the expiration of all the patents associated with the licensed patent rights, or until such time as we elect to terminate with 30 days’ notice. This license is limited to the fields of human diagnostic testing utilizing our solid chip surface detection and contains diligence and U.S. preference provisions. To date, these technologies have resulted in three issued U.S. patents, one issued European patent and one pending international patent family. In addition, these technologies may include related technologies that BioHelix may develop in the future. The BioHelix technologies are the basis of our nucleic acid amplification approach. In May of 2013, Quidel Corporation, a competitor of ours, purchased BioHelix. We pay a royalty fee for the licensing of this technology based on a percentage of our “Net Sales” of assays using these technologies (as defined in the license agreement).
Appears in 1 contract
Sources: Securities Purchase Agreement (Great Basin Scientific, Inc.)
IDT. In August 2010, we entered into a license agreement with Integrated DNA Technologies, or IDT, related to the use of blocked primers in combination with HDA. The term of this license agreement extends until the expiration of all the patents associated with the licensed patent rights, or until such time as we elect to terminate with 90 days’ notice. The license is exclusive to the fields of amplification utilizing HDA and detection of diagnostic targets in human in-vitro diagnostic testing, but is non-exclusive to all oncology and human papilloma virus targets or markers. These technologies have resulted in four pending U.S. patent applications and one issued European patent. We pay a royalty fee for the license of this technology based on a percentage of our “Net Sales” of products using these technologies (as defined in the license agreement). See Schedule 3(v)(i). Wrongful termination complaint filed in the United States District Court in and for the District of Utah, Central Division by a former employee, ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, against Great Basin Scientific, Inc. on June 15, 2016. Patent Title US 14/108,630 Systems and methods for point of care amplification and detection of nucleic acids (continuation, HDA, kit claims) CA2715890 Systems and methods for point of care amplification and detection of nucleic acids (general method) EP15182599.9 (divisional from ‘84) Systems and methods for point of care amplification and detection of nucleic acids (general method) EP08853920.0 Methods and compositions for amplifying a detectable signal US 14/949,240 Methods and compositions for amplifying a detectable signal (continuation, generalize target, methods of use/prep) CA2705984 Methods and compositions for amplifying a detectable signal US 13/911,878 Analyzer and Disposable Cartridge for Molecular In Vitro Diagnostics CA2881200 Characterization of a blocked-primer mediated isothermal amplification system JP2014-557780 Characterization of a blocked-primer mediated isothermal amplification system EP13748794.8 Methods of Isothermal Amplification Using Blocked Primers (system/kit claims) HK 15105687.0 Methods of Isothermal Amplification Using Blocked Primers (system/kit claims) US 14/565,696 Methods of Isothermal Amplification Using Blocked Primers (methods claims) US 14/883,018 SPECIFIC DETECTION OF ORGANISMS DERIVED FROM A SAMPLE (methods claims) US 14/7452,345 SPECIFIC DETECTION OF ORGANISMS DERIVED FROM A SAMPLE (kit claims) Patent Title Holder PCT/US2006/000406 Identification of RNA targets using helicase BioHelix 12/507,142 Rnase-H-based assays utilizing modified RNA monomers (bp method) IDT 13/839,334 Rnase-H-based assays utilizing modified RNA monomers (RNA targets) IDT 13/429,077 Rnase-H-based assays utilizing modified RNA monomers (Hot start language) IDT BioHelix. We hold non-exclusive licenses to key technologies from BioHelix related to isothermal amplification of nucleic acid targets, utilizing helicase-dependent amplification, or HDA. The term of this license agreement extends until the expiration of all the patents associated with the licensed patent rights, or until such time as we elect to terminate with 30 days’ notice. This license is limited to the fields of human diagnostic testing utilizing our solid chip surface detection and contains diligence and U.S. preference provisions. To date, these technologies have resulted in three issued U.S. patents, one issued European patent and one pending international patent family. In addition, these technologies may include related technologies that BioHelix may develop in the future. The BioHelix technologies are the basis of our nucleic acid amplification approach. In May of 2013, Quidel Corporation, a competitor of ours, purchased BioHelix. We pay a royalty fee for the licensing of this technology based on a percentage of our “Net Sales” of assays using these technologies (as defined in the license agreement).
Appears in 1 contract
Sources: Securities Purchase Agreement (Great Basin Scientific, Inc.)